DE69329687D1 - Verwendung von aspirin zur herstellung eines arzneimittels zur verbesserung fer blutperfusion des uterus - Google Patents

Verwendung von aspirin zur herstellung eines arzneimittels zur verbesserung fer blutperfusion des uterus

Info

Publication number
DE69329687D1
DE69329687D1 DE69329687T DE69329687T DE69329687D1 DE 69329687 D1 DE69329687 D1 DE 69329687D1 DE 69329687 T DE69329687 T DE 69329687T DE 69329687 T DE69329687 T DE 69329687T DE 69329687 D1 DE69329687 D1 DE 69329687D1
Authority
DE
Germany
Prior art keywords
pct
aspirin
improvement
production
medicinal product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69329687T
Other languages
English (en)
Other versions
DE69329687T2 (de
Inventor
Michael Macnamee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Applied Research Systems ARS Holding NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems ARS Holding NV filed Critical Applied Research Systems ARS Holding NV
Application granted granted Critical
Publication of DE69329687D1 publication Critical patent/DE69329687D1/de
Publication of DE69329687T2 publication Critical patent/DE69329687T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Semiconductor Lasers (AREA)
DE69329687T 1992-12-30 1993-12-24 Verwendung von aspirin zur herstellung eines arzneimittels zur verbesserung fer blutperfusion des uterus Expired - Fee Related DE69329687T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929227123A GB9227123D0 (en) 1992-12-30 1992-12-30 Method
PCT/GB1993/002657 WO1994015613A1 (en) 1992-12-30 1993-12-24 Use of cyclooxygenase inhibitors for the manufacture of a medicament for enhancing uterine blood perfusion

Publications (2)

Publication Number Publication Date
DE69329687D1 true DE69329687D1 (de) 2000-12-21
DE69329687T2 DE69329687T2 (de) 2001-05-10

Family

ID=10727336

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69329687T Expired - Fee Related DE69329687T2 (de) 1992-12-30 1993-12-24 Verwendung von aspirin zur herstellung eines arzneimittels zur verbesserung fer blutperfusion des uterus

Country Status (13)

Country Link
US (2) US5760024A (de)
EP (1) EP0691847B1 (de)
JP (1) JP3881690B2 (de)
AT (1) ATE197545T1 (de)
AU (1) AU683035B2 (de)
CA (1) CA2151476C (de)
DE (1) DE69329687T2 (de)
DK (1) DK0691847T3 (de)
ES (1) ES2151922T3 (de)
GB (1) GB9227123D0 (de)
GR (1) GR3035358T3 (de)
PT (1) PT691847E (de)
WO (1) WO1994015613A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9227123D0 (en) * 1992-12-30 1993-02-24 Applied Research Systems Method
EP1123687A3 (de) * 2000-02-10 2004-02-04 Aloka Co., Ltd. Diagnostisches Ultraschallgerät
US6695766B2 (en) 2002-04-26 2004-02-24 Olympia Womens Health Magnetic embryo transfer
EP1670902A4 (de) * 2003-09-08 2008-05-07 Univ Texas Verfahren und zusammensetzung zur verbesserung der embryoentwicklung in vitro durch ergänzen des kulturmediums mit prostaglandin oder einem prostaglandinanalogen
EP2987855B1 (de) 2004-05-17 2018-11-21 The General Hospital Corporation Isolierung von weiblichen keimbahnstammzellen
US7705197B2 (en) * 2005-01-19 2010-04-27 University Of Tennessee Research Foundation Embryo development and survival
US7615585B2 (en) * 2007-04-19 2009-11-10 Troy Corporation Degassing compositions for curable coatings
AU2012242591B2 (en) 2011-04-14 2014-10-23 The General Hospital Corporation Compositions and methods for autologous germline mitochondrial energy transfer
WO2013002880A1 (en) 2011-06-29 2013-01-03 The General Hospital Corporation Compositions and methods for enhancing bioenergetic status in female germ cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO91014B1 (ro) * 1984-12-08 1987-02-28 Raisa Motocescu Gel hormonal si antiprostaglandinic
KR920700648A (ko) * 1989-05-05 1992-08-10 오닐 크리스토퍼 가임성 향상
GB9227123D0 (en) * 1992-12-30 1993-02-24 Applied Research Systems Method

Also Published As

Publication number Publication date
ES2151922T3 (es) 2001-01-16
PT691847E (pt) 2001-02-28
DK0691847T3 (da) 2000-12-11
US6100249A (en) 2000-08-08
JPH08510717A (ja) 1996-11-12
US5760024A (en) 1998-06-02
EP0691847A1 (de) 1996-01-17
AU683035B2 (en) 1997-10-30
WO1994015613A1 (en) 1994-07-21
GB9227123D0 (en) 1993-02-24
GR3035358T3 (en) 2001-05-31
DE69329687T2 (de) 2001-05-10
CA2151476C (en) 2005-05-24
ATE197545T1 (de) 2000-12-15
CA2151476A1 (en) 1994-07-25
EP0691847B1 (de) 2000-11-15
JP3881690B2 (ja) 2007-02-14
AU5711394A (en) 1994-08-15

Similar Documents

Publication Publication Date Title
PT799209E (pt) Novas sulfonamidas
SE9401406D0 (sv) Pharmaceutical products for curing tumourous diseases and process for preparing same
ATE213164T1 (de) Verwendung von nona- und dekapeptiden zur herstellung eines arzneimittels zur bekämpfung von aids
KR960701051A (ko) 이미다조피리딘 및 이를 위장 질환의 치료에 사용하는 방법(imidazopyridines and their use in treating castrointestinal diseases)
ATE217197T1 (de) Verwendung von hyaluronsäure und eines nsaid zur herstellung eines arzneimittels zur behandlung von krankheiten der mucosa
ATE191849T1 (de) Verwendung von (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidinacetamid zur herstellung eines medikaments zur behandlung von angst
DE69329687D1 (de) Verwendung von aspirin zur herstellung eines arzneimittels zur verbesserung fer blutperfusion des uterus
DE3850154T2 (de) Verwendung von Gepiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung atypischer Depression.
DE69432124D1 (de) Verwendung eines inositoltriphosphatester, zur herstellung eines medikamentes
ATE223721T1 (de) Edelfosin zur behandlung von hirntumoren
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
ATE143947T1 (de) N-acylpyrrolidine und arzneimittel zur behandlung oder prophylaxe von mit ckk und gastrin in zusammenhang stehenden krankheiten
ATE194076T1 (de) Verwendung von n,s-diacetylcystein-ethylester (dacee) zur herstellung eines medikaments zur behandlung viraler erkrankungen
DE69626301T2 (de) Verwendung von allylaminderivaten wie terbinafin zur herstellung eines medikaments zur behandlung von mit einer helicobacter pylori infektion zusammenhängenden erkrankungen
ATE312611T1 (de) Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen
ATE186640T1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung neurogenerativer erkrankungen
ES2137665T3 (es) Nuevos derivados de piridina o piridazina, procedimientos para su preparacion, y medicamentos que contienen estos compuestos.
ATE232867T1 (de) Tetronsäurederivate zur behandlung von hiv- und anderen retroviruserkrankungen
DE69428797T2 (de) Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden
ATE203671T1 (de) Imidazolochinoxalinone zur behandlung zentralnervöser erkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN

8327 Change in the person/name/address of the patent owner

Owner name: LABORATOIRES SERONO S.A., COINSINS, VAUD, CH

8339 Ceased/non-payment of the annual fee